FDA Approves Dual-Action Drug for Patients With Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
March 27, 2025
March 27, 2025
BOSTON, Massachusetts, March 27 -- The Dana-Farber Cancer Institute issued the following news release:
* * *
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by t . . .
* * *
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by t . . .